Endocannabinoid
Resource Center
TOP ARTICLES
FDA Announces Early Fall Cannabidiol Hearings and Clarifies Commitment to Enforcement
The FDA announced that it will host further cannabidiol hearing on the regulatory structure of CBD products in the early fall. The news was embedded in a press release regarding a warning issued to a CBD maker CuraLeaf for making unfounded claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain
Medicinal Cannabis Reduces or Ends Seizures in Children with Severe, Drug-resistant Epilepsy
Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a study by the University of Saskatchewan (USask), Canada has found. Children with severe drug-resistant epilepsy also experienced improvements in their quality of life after taking
Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptoms
International Cannabinoid Research Society (ICRS) Names Cannabis and Cannabinoid Research Its Official Journal
New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR its Official Journal. The ICRS is a foremost international society spearheading scientific research in all fields of cannabinoids, ranging from biochemical, chemical, and physiological studies
Four Articles: Cannabis and Cannabinoid Use in Palliative Care, Open Access until May 6, 2019
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians in recommending cannabis and cannabinoid use is not yet well developed. The Journal of Palliative Care, David Casarett, MD, Guest Editor and Chief of Palliative Care
Interaction of Neurotransmitters and Neurochemicals with Lymphocytes, including the Endocannabinoid System
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health and
Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In this study, published in the journal Neurology, researchers evaluated medical cannabis’ (MC) efficacy and adverse effects (AE) in patients 75 years of age or older.
